Embedding a Clinical QA Consultant for Phase 3 QMS Development
Six months to inspection-ready. Here's a look inside the clinical QMS build that took a small sponsor from Phase 2 success to Phase 3 first patient enrolled.
Most small pre-commercial sponsors don’t have the luxury of spending much time thinking about what happens if their drug actually makes it out of Phase 1 and 2 trials.
Most of the time, these teams are small, the budgets are tight, and the procedures that exist are good enough to keep things moving. But it’s rare to see anyone writing inspection-readiness checklists when the question is still whether the molecule does what they think it might.
For the fortunate, Phase 2 data comes back strong and the timeline to Phase 3 stops being theoretical. And that’s usually when a sort of panic sets in: the FDA is going to show up at some point, and what’s been good enough for early-phase work isn’t going to hold up under a Phase 3 inspection.
That’s exactly where one of our recent clinical staff augmentation projects started. We placed one of our clinical QA consultants, Ranee Moor, with a small biotech sponsor that found itself in exactly this position. They had promising results, a Phase 3 trial to plan, and a quality system that wasn’t built for what was coming next.
Here’s how the next six months played out to give you an idea of how the right embedded outsider can make an enormous difference across clinical operations on a short timeline.
What the gap analysis turned up
Ranee’s first task was a gap analysis in June of last year. The goal was to identify everything that would be a problem if the FDA came in for a Phase 3 inspection.
The list turned out to be pretty long:
The sponsor had SOPs, but they were hard to follow and didn’t give people enough detail to know what to actually do in many cases.
There were no work instructions, no forms, no templates backing up the procedures.
Entire categories were missing: no SOP for sponsor oversight, no process for internal monitoring, no inspection readiness training or checklists. No learning management system. No document management system. And the budget to license one wasn’t there.
A prior CRO qualification was on file, but it didn’t hold up when you looked at it closely. The internal QA function was just two people, one of whom was still getting oriented in clinical quality.
None of this is unusual for a company at this stage, of course. Small sponsors regularly get through early-phase work on momentum. The problem only becomes urgent when Phase 3 forces the question of whether you can defend your processes to a regulator.
Establishing a weekly work cadence
The substantive work started in September. Ranee partnered with an SOP author from our team, and they set up a production cadence that the sponsor’s reviewers could keep up with without drowning.
Here’s what that looked like:
Every Thursday, a new topic package went out. Each package included one SOP, three or four work instructions, and all the supporting forms. The review team had a representative from every functional department. Everyone got a single email with a link, and they had one week.
The following Monday, a round-two version came back with comments addressed. The review window for round two was shorter, since the team had already seen the document and was mostly confirming that feedback was incorporated.
A QC reviewer on the sponsor’s side then ran line-by-line checks before anything went to final approval: consistency of defined terms across documents, numbering, formatting, and cross-references. By the time an SOP package reached sign-off, it had been through a tight, repeatable process.
They ran a cadence of one topic per week, twenty to thirty topics total. Document management came first, then training management, then sponsor oversight, then vendor management, then on down the list. The sequencing here was intentional, since Ranee needed the vendor management SOP ready before she could start qualifying vendors for the Phase 3 trial. That topic had to come early. Inspection readiness could wait a couple months, so it went later. Every topic was ordered around what the clinical work actually needed and when it needed it.
Running ClinOps work in parallel
While the QMS was getting written, Ranee was handling the clinical side of Phase 3 startup:
Protocol review
Master informed consent
CRO selection and qualification
Quality agreements
Vendor management plans
Communication plans
As each new SOP was approved, she put it to use immediately.
The philosophy was three tiers of work happening at once. First, build the process. Second, produce the deliverables the process calls for. Third, generate the evidence that the process is actually being followed.
That third tier is where we see a lot of sponsors fall short. It’s one thing to have an SOP that requires meetings to have an agenda and minutes. It’s another to actually put meetings on the calendar, send the agendas, store the minutes, and be able to point to all of it during an inspection.
Ranee spent quite a bit of her time on that gap between having a procedure and living by it. If the SOP said an agenda was required, where was the agenda? If it said minutes had to be stored, where were they going? The SOP had to reflect the way people actually worked now.
A CRO timeline problem
The CRO selected for the Phase 3 trial had committed to a set of deliverables on a timeline that started in October: A comms plan, monitoring plan, safety management plan, data management plan, and risk plan. October passed, then November. Then December. Then January!
Status updates kept reading “drafting” with no dates attached.
In January, Ranee started running separate meetings and pushing for firm delivery dates instead of status labels. Everything showed up at once in February. The sponsor’s team had days, not weeks, to review plans that had originally been promised months earlier. They divided the work and got everything signed off before the first patient enrolled.
This kind of “CRO slippage” is common, and it’s one of the reasons Ranee’s role extended well beyond QMS authoring. Someone had to own the tracking and the follow-up, and neither the CRO’s internal processes nor the sponsor’s small team was positioned to catch the delays on their own. That accountability function turned out to be just as important as the documents themselves. We often embed consultants simply to serve as a strong manager between the sponsor and CRO, given the sensitive politics that get in the way when there isn’t an outside party.
Training built into every conversation
One thing that set this project apart from a pure document build was that Ranee treated every interaction as a training exercise. She walked people through why each decision mattered and how to defend it if a regulator asked. When prior work needed to be upgraded, she framed it as an improvement, not criticism.
“You did a great job with the information you had. Here’s what we want to improve on and why.”
By the end of the engagement, the sponsor’s internal QA contact had grown from someone who was still learning the function into a confident operator who understood the system and could run it independently. That growth happened because they were explained the reasoning behind every decision, not just the output. Six months of that adds up.
Wrapping in a ready state
The first Phase 3 patient was enrolled in March, ahead of the original date. The sponsor had a working quality management system, qualified vendors, executed agreements, and two inspection-readiness checklists (one for pre-first-patient, one for trial close) that the team was actively tracking against.
At that point, the sponsor hired a full-time QA lead — Ranee essentially worked herself out of the job. Still, she spent two weeks onboarding him, walking through what had been built, where things stood, and what needed ongoing attention.
And then the engagement was over. The sponsor didn’t need outside help anymore. As Ranee put it, she had to build the room before the furniture could come in. By March, the room was built, the furniture was in place, and the people inside it knew how to keep it organized.
What made it work
We asked Ranee for her take on why this project succeeded given how much was working against that outcome. She said it came down to the people:
The sponsor acknowledged their weaknesses without taking it personally.
They welcomed direction instead of resisting it.
When someone’s prior work needed to be redone, the team took the feedback and improved.
Both sides matched each other’s energy and hours. Trust built quickly because the working relationship worked.
The same consultant placed with a less receptive team might have delivered the same documents, but not the same outcome. The quality system works today because the people who now own it understand it and believe in it. That’s the part that can’t be copied from a template.
What she’d tell the next small sponsor
When asked what advice she’d give to other sponsors heading into a similar situation, Ranee’s answer had less to do with the mechanics of documentation strategy and more to do with being in the right mindset to accept the help:
Acknowledge the weaknesses. That’s the starting point. Small companies get through early phases with what they have, and much of what exists was put together by the same people who are still in the room when the consultant shows up. The CRO qualification that needed to be redone? Someone on the team wrote it. The SOPs that needed a full rewrite? Someone signed off on them. That’s a sensitive position to walk into. Ranee made a habit of telling people they did a good job with what they had, and then showing them what “better” looked like and why it mattered. When improvements are framed as building on what’s there rather than tearing it down, people stay open. When they feel like criticism, people shut down. That distinction determined the tone of the entire engagement.
The other part is energy. This project worked partly because the sponsor’s team was online at just about all hours, responding to comments, meeting review deadlines, and pushing just as hard as Ranee was. She was clear about that: her recommendations wouldn’t have changed with a different team. But they wouldn’t have been heard and received the same way. The willingness to listen is what turned a stack of new SOPs into a quality system people actually followed.
None of that is specific to this sponsor or this drug. Any small company approaching a Phase 3 transition is going to face some version of this problem. The ones that come out of it ready for inspection tend to share two things: they accept that their early-phase systems won’t scale, and they’re willing to let someone come in and help them build what’s next.
Ranee Moor is a Clinical QA Consultant with The FDA Group. She has more than 25 years of experience in pharmaceutical quality across GCP, GMP, GLP, and computer systems validation. She runs Quality Systems & Technology, Inc., an independent QA consulting firm, and has held senior QA, validation, and IT compliance roles at Charles River Laboratories, ICON plc, and META Solutions. She’s represented sponsor organizations during regulatory inspections and led validation and quality system efforts for both small biotechs and large CROs.
Need expert clinical support?
If you’re approaching a Phase 3 transition, a planned inspection, or any milestone where your quality system needs to be ready faster than internal capacity allows, this is the kind of work we do every week.
We place clinical QA consultants inside sponsor organizations on short notice, sometimes within days, to build out or take over quality systems alongside your internal team. They come in ready to work, without the ramp time of a new hire or the cost of a permanent headcount.
To talk through your situation or request a consultant, reach out to us.
Who is The FDA Group?
The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus on Quality Assurance, Regulatory Affairs, and Clinical Operations.
With thousands of resources worldwide, hundreds of whom are former FDA, we meet your precise resourcing needs through a fast, convenient talent selection process supported by a Total Quality Guarantee. Learn more and schedule a call with us to see if we’re a fit to help you access specialized professionals and execute your projects on time and on budget.